Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 49Leukemia 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia, Myelomonocytic, Acute 11Leukemia, Monocytic, Acute 10Myelodysplastic Syndromes 7Leukemia, Erythroblastic, Acute 7Burkitt Lymphoma 7Lymphoma 6Leukemia, Megakaryoblastic, Acute 6Leukemia, Biphenotypic, Acute 6Myeloproliferative Disorders 4Dendritic Cell Sarcoma, Interdigitating 4Thrombocytopenia 3Lymphoma, Non-Hodgkin 3Leukemia, Promyelocytic, Acute 3Congenital Abnormalities 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Neutropenia 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Basophilic, Acute 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms 1Lymphoma, T-Cell 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Daunorubicin × Clear all
NCT03286634 2026-05-11

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

National Hospital Organization Nagoya Medical Center

Phase 2 Active not recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Down Syndrome, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡